Unlocking the true power of PET
We radically improve your ability to diagnose, study, and treat disease
Radiopharmaceuticals for the modern world
Our radiolabeling platform radically improves the resolution, safety, use, and cost of PET imaging.
PET scans are critical for detecting and diagnosing disease in clinical settings, but their true potential remains largely untapped.
A single, disease-agnostic platform that scales
For the first time, we are making it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single disease-agnostic chemistry platform.
Our patented HetSiFA™ compositions, synthesized using our alkali metal catalysts, can attach to any disease-targeting ligand.
Our process for radiolabeling any ligand depends on a scalable reaction that works at any quantity, and our approach has demonstrated record-breaking radiolabeling efficiency with fluorine-18.Learn More
Solving for existing challenges
Accelerating drug discovery
Valuable from the earliest stages of drug discovery, PET imaging of new drug candidates provides unique pharmacokinetic information and quantification of drug properties in vivo. Our radiolabeling platform can make PET a ubiquitous, essential, and cost-effective tool that improves decision-making and increases returns on R&D investment throughout all stages of the drug development process.
We apply Fuzionaire’s core chemistry, based on alkali metal catalysts, to make new radiotracers.Read More
Get in touch
If you are interested in learning more about our radiobeling platform, we want to hear from you.Contact